

**Onco-Nephrology Controversies and Case Discussions, Onco-Nephrology Controversies and Case Discussions - 2/19/2021, Improving on the Adrogue-Madias equation - 3/26/2021, Managing Kidney Stress in the ICU, Onco-Nephrology Controversies and Case Discussions - 5/21/2021, Onco-Nephrology Controversies and Case Discussions - 6/18/2021, Onco-Nephrology Controversies and Case Discussions - 7/16/2021, Onco-Nephrology Controversies and Case Discussions - 8/20/2021, Onco-Nephrology Controversies and Case Discussions - 9/17/2021, Onco-Nephrology Controversies and Case Discussions - 10/15/2021, Onco-Nephrology Controversies and Case Discussions - 11/19/2021, Onco-Nephrology Controversies and Case Discussions - 12/17/2021**

**Presented by**

**Friday February 19, 2021**

**12:00 PM**

**Online**

**Target Audience:**

Specialties: General Oncology, Internal Medicine, Other

Professions: Physician (MD or DO), Student or Trainee

**Error! Unknown op code for conditional.**

**Learning Objectives:**

1 Diagnose the common renal complications arising from cancer and its treatments (onconephrology).

2 Recognize and treat a spectrum of renal syndromes including: sepsis, acid-base, electrolyte disorders and other disorders.

3 Anticipate novel diagnostic and therapeutic strategies for renal disease.



**Accreditation:**

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Designation:**

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Commercial Support:**

No commercial support has been received for this activity.

**Faculty & Planner Disclosure:**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of commercial interest/Nature of relationship** |
| Sheldon Chen, MD | Activity Co-Director/Chair | Nothing to disclose - 12/18/2020 |
| Biruh Workeneh, MD | Activity Director/Chair | Nothing to disclose - 01/12/2021 |
| Samaya Anumudu, MD | Other Planning Committee Member | Nothing to disclose - 01/10/2021 |
| Hassan Ibrahim, MD | Other Planning Committee Member | Paid consultant-Other-Relypsa Pharma|Membership on advisory committees or review panels, board membership, etc.-Other-Exosome Diagnostics - 01/14/2021 |
| Sreedhar Mandayam, MD | Other Planning Committee Member | Nothing to disclose - 12/18/2020 |
| Kevin Mulpur, MBA | Other Planning Committee Member | Nothing to disclose - 01/12/2021 |

**Hardware & Software Requirements:**

If this activity includes a virtual meeting, the technical requirements are as follows:

**System Requirements:**

Internet Connection – broadband wired or wireless (3G or 4G/LTE)

Speakers – built-in or wireless Bluetooth

**Windows:**

Internet Browser – Internet Explorer 11+, Edge 12+, Firefox 27+, Chrome 30+

Operating System – Windows 10 Home, Pro, or Enterprise. S Mode is not supported.

**Apple:**

Internet Browser – Safari 7+, Firefox 27+, Chrome 30+

Operating System macOS 10.9 or later

**Processor Requirements:**

Minimum – Single-core 1GHz or higher

Recommended – Dual-core 2GHz or higher (Intel i3/i5/i7 or AMD equivalent)

**RAM Requirements:**

Minimum – N/A

Recommended – 4GB

**Bandwidth:**

50 - 70kbps (down)

**Supported Tablet and Mobile Devices:**

Surface PRO 2 or higher and running Windows 8.1 or higher

iOS and Android devices

Blackberry devices